TCGX Acquisition has filed with the U.S. Securities and Exchange Commission (SEC) to raise up to $75 million through an initial public offering as the special purpose acquisition company (SPAC) looks to pursue business combination opportunities within Asia’s healthcare industry.

The Palo Alto, California-based company plans to offer 7.5 million shares priced at $10 per share, seeking gross proceeds of approximately $75 million. Unlike most SPAC offerings, TCGX Acquisition will not issue units containing warrants or rights, instead offering common shares only.

The company intends to list on the Nasdaq under the ticker symbol TCGX.

Focused on Healthcare Opportunities Across Asia

TCGX Acquisition intends to identify and merge with businesses operating in the life sciences and medical technology sectors throughout Asia, where healthcare demand continues to expand due to demographic shifts, rising healthcare expenditures, technological innovation, and increased investment across the region.

The company believes the sector offers attractive long-term growth opportunities driven by aging populations, expanding access to healthcare services, advances in biotechnology, and increasing adoption of medical technologies.

By concentrating exclusively on healthcare, TCGX Acquisition aims to leverage industry expertise to identify companies with strong growth potential and scalable business models.

Experienced Leadership Team

The SPAC is led by Chief Executive Officer and Director Chen Yu, the founder and Managing Member of TCG Crossover (TCGX). Supporting the leadership team is Chief Financial Officer and Director Craig Skaling, who also serves as Chief Financial Officer and Chief Operating Officer of TCGX.

Management intends to utilize its investment experience and industry relationships to source acquisition candidates that can benefit from access to U.S. public capital markets while accelerating their long-term growth strategies.

Differentiated SPAC Structure

Unlike traditional SPAC offerings that package shares with warrants or other securities, TCGX Acquisition has chosen a simplified capital structure consisting solely of common shares. This approach may reduce potential shareholder dilution following a future business combination while providing investors with more direct equity exposure.

The structure also reflects a growing trend among some newer SPAC issuers seeking to align investor interests more closely with long-term value creation.

Filing Marks Latest Healthcare-Focused SPAC Launch

Founded in 2026, TCGX Acquisition confidentially submitted its registration statement to the SEC on June 23, 2026. Jefferies is serving as the sole bookrunner for the offering.

The IPO proceeds will be placed into a trust account until the company completes an initial business combination or returns capital to investors if no qualifying transaction is completed within the required timeframe.

Closing Insights

TCGX Acquisition enters the public markets with a focused strategy centered on Asia’s rapidly growing healthcare industry. By targeting companies in life sciences and medical technology and utilizing a streamlined SPAC structure without warrants, the company seeks to differentiate itself while pursuing acquisition opportunities in one of the world’s fastest-growing healthcare markets. Investors will closely watch management’s ability to identify an attractive merger partner capable of delivering sustainable long-term growth.